Bioasis Announces Director Resignation
November 25 2019 - 4:05PM
Business Wire
BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), (the
“Company” or “Bioasis”), a pre-clinical, research-stage
biopharmaceutical company developing its proprietary xB3 ™ platform
technology for the delivery of therapeutics across the blood-brain
barrier (“BBB”) and the treatment of central nervous system (“CNS”)
disorders in areas of high unmet medical need, including brain
cancers and neurodegenerative diseases, today announced that, in
light of the significant demands placed on her time by a number of
other business commitments, Dr. Nancy Stagliano has resigned as a
director of the company.
“Nancy has played a key role in providing oversight and guidance
to Bioasis over the past two years,” said Dr. Deborah Rathjen,
Executive Chair and Chief Executive Officer of Bioasis. “We are
grateful for her contributions and wish her well in her other
endeavours.”
Given Dr. Stagliano’s resignation, she will no longer be
standing for re-election at the Company’s annual meeting of
shareholders to be held on December 5, 2019. As a result, only the
four remaining members of Bioasis’ board of directors (being Dr.
Deborah Rathjen, John Curran, David Wurzer and Dr. Mario
Saltarelli) will be nominated for election at the meeting.
About Bioasis Bioasis Technologies Inc. is a
biopharmaceutical company developing the xB3 ™ platform, a
proprietary technology for the delivery of therapeutics across the
blood brain barrier and the treatment of CNS disorders in areas of
high unmet medical need, including brain cancers and
neurodegenerative diseases. The delivery of therapeutics across the
blood brain barrier represents the final frontier in treating
neurological disorders. The in-house development programs at
Bioasis are designed to develop symptomatic and disease-modifying
treatments for brain-related diseases and disorders. The Company
maintains headquarters in Guilford, Conn., United States. Bioasis
trades on the TSX Venture Exchange under the symbol “BTI” and on
the OTCQB under the symbol “BIOAF.” For more information about the
company, please visit www.bioasis.us.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191125005774/en/
On behalf of the Board of Directors of Bioasis Technologies
Inc. Deborah Rathjen, Ph.D., Executive Chair of the Board
deborah@bioasis.us +1 203 533 7082
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Apr 2023 to Apr 2024